Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients

Annals of the New York Academy of Sciences

Volumn 1075, Issue , 2006, Pages 197-203

  Taback, Bret ^a   Saha, Sukamal ^b   Hoon, Dave S B ^c  

^a NewYork Presbyterian Hospital   (United States)

^b MCLAREN REGIONAL MEDICAL CENTER   (United States)

^c JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Circulating tumor DNA; Colorectal cancer; Loss of heterozygosity; Methylation; Serum

Indexed keywords

DNA; TUMOR MARKER;

BLOOD LEVEL; BLOOD SAMPLING; CANCER DIAGNOSIS; CHROMOSOME; CLINICAL ARTICLE; COLORECTAL CANCER; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; DNA DETERMINATION; DNA ISOLATION; DNA METHYLATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; LIVER; MESENTERIC VEIN; MGMT GENE; MICROSATELLITE MARKER; NUCLEIC ACID ANALYSIS; PERIPHERAL VEIN; PORTAL VEIN; QUANTITATIVE ANALYSIS; RAR BETA2 GENE; RASSF1A GENE; SENSITIVITY AND SPECIFICITY; SYSTEMIC CIRCULATION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

EID: 33749557860     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1368.027     Document Type: Conference Paper

References (28)

1. JEMAL, A. et al. 2005. Cancer statistics, 2005. C. A. Cancer J. Clin. 55: 10-30.
2. VOGELSTEIN, B. et al. 1988. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319: 525-532.
3. BAKER, S.J. et al. 1989. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244: 217-221.
4. TOYOTA, M. et al. 1999. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 96: 8681-8686.
5. ESTELLER, M. et al. 2001. A gene hypermethylation profile of human cancer. Cancer Res. 61:3225-3229.
6. KOPELOVICH, L. et al. 2003. The epigenome as a target for cancer chemoprevention. J. Natl. Cancer Inst. 95: 1747-1757.
7. KONDO, Y. & J.P. ISSA. 2004. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 23: 29-39.
8. HERMAN, J.G. 2002. Hypermethylation pathways to colorectal cancer: implications for prevention and detection. Gastroenterol. Clin. North Am. 31: 945-958.
9. CHEN, X.Q. et al. 1996. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat. Med. 2: 1033-1035.
10. GOESSL, C. et al. 1998. Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma. Cancer Res. 58: 4728-4732.
11. KAWAKAMI, K. et al. 2000. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl. Cancer Inst. 92: 1805-1811.
12. NAWROZ, H. et al. 1996. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat. Med. 2: 1035-1037.
13. KOLBLE, K. et al. 1999. Microsatellite alterations in serum DNA of patients with colorectal cancer. Lab. Invest. 79: 1145-1150.
14. SORENSON, G.D. 2000. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin. Cancer Res. 6: 2129-2137.
15. TABACK, B. et al. 2001. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res. 61: 5723-5726.
16. TABACK, B. et al. 2001. Microsatellite alterations detected in the serum of early stage breast cancer patients. Ann. N. Y. Acad. Sci. 945: 22-30.
17. Lo, Y.M. et al. 2000. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res. 60: 2351-2355.
18. WANG, J.Y. et al. 2004. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J. Surg. 28: 721-726.
19. TABACK, B. & D.S. HOON. 2004. Circulating nucleic acids and proteomics of plasma/serum: clinical utility. Ann. N. Y. Acad. Sci. 1022: 1-8.
20. HIBI, K. et al. 1998. Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res. 58: 1405-1407.
21. GRADY, W.M. et al. 2001. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 61: 900-902.
22. TABACK, B. & D.S. HOON. 2004. Microsatellite alterations as diagnostic and prognostic molecular markers in patients with cancer. In Cancer Diagnostics: Current and Future Trends. R. Nakamura, et al., Eds.: 395-428. Humana Press. Totowa, NJ.
23. FUJIMOTO, A. et al. 2004. Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome. Cancer Res. 64: 4085-4088.
24. HOON, D.S. et al. 2004. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23: 4014-4022.
25. SHINOZAKI, M. et al. 2005. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin. Cancer Res. 11: 2156-2162.
26. JONES, P.A. & S.B. BAYLIN. 2002. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3: 415-428.
27. HANAHAN, D. & R.A. WEINBERG. 2000. The hallmarks of cancer. Cell 100: 57-70.
28. ANKER, P. et al. 1999. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev. 18: 65-73.